

Clinical Development and Commercialization of NG101: A Gene Therapy for Wet Age-Related Macular Degeneration



OPHTHALMOLOGY	Phase 2
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Wet Age-Related Macular Degeneration (wet AMD)
Target	Vascular Endothelial Growth Factor (VEGF)-A, VEGF-B, PIGF (placental growth factor)
MoA(Mechanism of Action)	AAV producing Aflibercept which acts as a decoy receptor for VEGF, therefore, reducing abnormal blood vessel growth and leakage in the eyes
Competitiveness	<ul style="list-style-type: none"> ✓ One-and-Done Approach: Single-dose administration delivers durable efficacy over multiple years ✓ Safety-First: <ul style="list-style-type: none"> • Proprietary Promoter CAT311 drives robust, sustained expression, enabling lower dosing. • Reduced doses minimis immunogenicity and toxicity risks. ✓ Lowest-Dose Phase 1/2a Clinical Trial Ongoing: Clinical trial initiated at the lowest dose among competitors, with interim data showing promising safety and efficacy. ✓ Cost efficiency: Durable expression at lower doses significantly reduces batch requirements and manufacturing costs – a key barrier in AAV gene therapy.
Development Stage	Phase 2
Route of Administration	Subretinal injection

Any unauthorized distribution or reproduction of this material is strictly prohibited.